Deerfield Management Company, L.P. (Series C) Delcath Systems, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 812,561 shares of DCTH stock, worth $8.84 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
812,561
Previous 813,106
0.07%
Holding current value
$8.84 Million
Previous $10.4 Million
6.76%
% of portfolio
0.25%
Previous 0.26%
Shares
4 transactions
Others Institutions Holding DCTH
# of Institutions
121Shares Held
13.2MCall Options Held
108KPut Options Held
40.5K-
Vanguard Group Inc Valley Forge, PA1.61MShares$17.5 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il803KShares$8.74 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA703KShares$7.65 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA570KShares$6.2 Million1.64% of portfolio
-
Marshall Wace, LLP London, X0483KShares$5.26 Million0.01% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $93.5M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...